gip and glp-1 LY3437943, a novel triple glucagon, GIP, receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Frontiers | Clinical perspectives on

These modify risk and may help decide how strongly to consider GLP-1 therapy for brain protection

Unlike oral supplements that can take weeks to show an effect, injections often provide noticeable improvements within days

For trips under 24 hours, this approach adequately protects most peptides

TRIUMPH-2 demonstrated up to 20.8% average weight loss (49.6 lbs) at 80 weeks in adults with obesity or overweight and type 2 diabetes TRIUMPH-3 showed up to 22.6% average weight loss (55.8 lbs) in adults with severe obesity and established cardiovascular disease Retatrutide delivered A1C reductions of up to 1.6% in participants with type 2 diabetes The highest dose improved key cardiometabolic markers, including triglycerides, blood pressure, waist circumference, and inflammation markers Lilly plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027 Advances the next generation of obesity medicines targeting weight management alongside broader metabolic health outcomes ------------------------------------------------------------- Stay up to date with everything obesity through my newsletter To view or add a comment, sign in 876 followers Explore related topics Trends in Glp-1 Treatment Options Advancements in Diabetes and Obesity Treatments Latest Developments in Type 1 Diabetes Research Cardiometabolic Therapies Under Development Impact of Glp-1 Medications on Health How Glp-1 Drugs Impact Economic Trends Recent Advances in Heart Disease Research Gut Metabolites Impact on Cardiovascular Health

Collectively, this tri-peptide formulation provides a multifaceted approach to studying regeneration, inflammation resolution, and extracellular matrix restoration in preclinical models GLP-1 5mg Summary Description: Semaglutide is a synthetic, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) used primarily for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in adults with overweight or obesity